Epilepsy

Published on 05/05/2015 by admin

Filed under Internal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1187 times

93 Epilepsy

Advanced-level questions

How would you manage epilepsy?

General advice: avoid ladders, heights, unsupervised swimming and cycling for 2 years from the last episode

Antiepileptic drugs: the first-line drugs for epilepsy monotherapy remain carbamazepine and sodium valproate; phenytoin is now used less often. Although lamotrigine has a monotherapy licence, its place has still to be defined. Several new ‘add on drugs’ have been licensed in recent years including vigabatrin, gabapentin, lamotrigine and topiramate. An overview of trials in patients with refractory partial seizures suggests no major differences between these agents in either efficacy or tolerability (BMJ 1996;313:1169–74). Prolonged use of vigabatrin can result in severe visual field defects, prompting the development of guidelines for monitoring vision (BMJ 1998;317:1322). The SANAD trial suggested that lamotrigine is the drug of first choice in patients with partial seizures, and valproate for patients with generalized or unclassified seizures in the absence of factors that would lead to an alternative choice. Valproic acid was more effective than lamotrigine and topiramate in generalized seizures. Lamotrigine had almost twice the failure rate because of inadequate seizure control, whereas topiramate was similarly effective in controlling seizures but had a higher failure rate caused by discontinuation because of side effects (Lancet 2007;369:1016–26). Ethosuximide and valproic acid were more effective than lamotrigine in the treatment of childhood absence epilepsy. Valproate, compared with other commonly used antiepileptic drugs, was associated with an increased risk of impaired cognitive function at 3 years of age and risk of birth defects. Therefore, it should be avoided as a first-choice drug in women of childbearing potential; risks of valproate should be balanced with the risks of uncontrolled seizures.

Vagal stimulation remains an experimental approach in seizure control (J Clin Neurophysiol 1997;14:358–68).

Advice about driving: those who have had more than one seizure are unable to hold a driving licence in the UK unless they have been free from any form of epileptic attack while awake for a period of 1 year before the issue of a licence or, in the case of attacks while asleep, these attacks must have occurred only while asleep over a period of 3 years and no awake attacks before the issue of a licence. Drivers of heavy goods vehicles and public service vehicles must have been free of epileptic attacks for at least the last 10 years and must not have taken anticonvulsant medications during this 10-year period.

Patients should be discouraged from participating in other activities for which a history of seizures increases the risk of injury or death, such as operating high-risk power equipment, working at heights and swimming or bathing alone.

Women who intend to use oral contraceptive pills and are taking phenytoin, carbamazepine, phenobarbital, topiramate or oxcarbazepine (these drugs induce hepatic enzymes to increases clearance of oral contraceptives) should be advised to use preparations containing at least 50 µg ethinylestradiol in order to reduce the chance of pregnancy. Valproate should also be avoided because of the risk of teratogenicity.